Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

790 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Medication "underuse" headache.
Rattanawong W, Rapoport A, Srikiatkhachorn A. Rattanawong W, et al. Among authors: rapoport a. Cephalalgia. 2024 Apr;44(4):3331024241245658. doi: 10.1177/03331024241245658. Cephalalgia. 2024. PMID: 38613233 Free article. Review.
Defibrotide improves COVID-19-related acute respiratory distress syndrome in myeloma patients after chimeric antigen receptor T-cell treatment without compromising virus-specific and anti-myeloma T-cell responses.
Kocoglu MH, Richardson PG, Mo CC, Rapoport AP, Atanackovic D. Kocoglu MH, et al. Among authors: rapoport ap. Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284793. Online ahead of print. Haematologica. 2024. PMID: 38385273 Free article.
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
Kline K, Luetkens T, Koka R, Kallen ME, Chen W, Ahmad H, Omili D, Iraguha T, Gebru E, Fan X, Miller A, Dishanthan N, Baker JM, Dietze KA, Hankey KG, Yared JA, Hardy NM, Rapoport AP, Dahiya S, Atanackovic D. Kline K, et al. Among authors: rapoport ap. Cancer Immunol Immunother. 2024 Feb 13;73(3):45. doi: 10.1007/s00262-023-03619-9. Cancer Immunol Immunother. 2024. PMID: 38349430 Free PMC article.
A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell products.
Atanackovic D, Iraguha T, Omili D, Avila SV, Fan X, Kocoglu M, Gebru E, Baker JM, Dishanthan N, Dietze KA, Oluwafemi A, Hardy NM, Yared JA, Hankey K, Dahiya S, Rapoport AP, Luetkens T. Atanackovic D, et al. Among authors: rapoport ap. Cytotherapy. 2024 Apr;26(4):318-324. doi: 10.1016/j.jcyt.2024.01.006. Epub 2024 Feb 10. Cytotherapy. 2024. PMID: 38340107
Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
Ghobadi A, Munoz J, Westin JR, Locke FL, Miklos DB, Rapoport AP, Perales MA, Reagan PM, McGuirk JP, Jacobson CA, Kersten MJ, Avivi I, Peng A, Schupp M, To C, Oluwole OO. Ghobadi A, et al. Among authors: rapoport ap. Blood Adv. 2024 Feb 5:bloodadvances.2023011532. doi: 10.1182/bloodadvances.2023011532. Online ahead of print. Blood Adv. 2024. PMID: 38315832
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.
Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos D, Neelapu SS, Locke FL, Ghobadi A. Jain MD, et al. Among authors: rapoport ap. Blood Adv. 2024 Feb 27;8(4):1042-1050. doi: 10.1182/bloodadvances.2023011489. Blood Adv. 2024. PMID: 38051550 Free PMC article.
790 results